Why choose Duodopa® for advanced Parkinson's disease?
Provides predictability of ON/OFF time2
Generally well-understood safety profile over 17 years since first approval1-4
>61,000 patient treatment years of exposure5
Up to 24 hours of continuous intestinal infusion with levodopa, if medically justified1
Avoids issues associated with erratic gastric emptying6
Can be used as monotherapy1,7
Find out more about Duodopa®
1. Duodopa® Summary of Product Characteristics, available on www.medicines.ie.
2. Fernandez HH, et al. Mov Disord 2015;30:500–9.
3. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu301035 (Accessed November 2022).
4. Antonini A, et al. Parkinsonism Relat Disord 2017;45:13–20.
5. Data on File. AbbVie, Inc., ABVRRTI72052.
6. Slevin JT, et al. J Parkinsons Dis 2015;5:165–74.
7. Fasano A, et al. Mov Disord. 2021; doi: 10.1002/mds.28596.
IE-DUOD-220028. Date of preparation: November 2022.
